Search company, investor...


Founded Year



Series G - II | Dead

Total Raised


Last Raised


About Sangart

Sangart is a biopharmaceutical company focused on oxygen-therapeutic agents, providing products to patients in need. Sangart was founded in 1998 based on discoveries arising from over two decades of research in red blood cell substitutes and the mechanisms of oxygen transport by cell-free hemoglobin solutions.

Headquarters Location

6175 Lusk Boulevard Suite 104

San Diego, California, 92121,

United States


Missing: Sangart's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sangart's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Sangart Patents

Sangart has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Amines, Proteins, Molecular biology, Biotechnology, Rare diseases


Application Date


Grant Date



Related Topics

Amines, Proteins, Molecular biology, Biotechnology, Rare diseases



Latest Sangart News

Artificial Blood Market Size Analysis, Evolving Opportunities Investigated for Forecast Period 2022-2029 | Dextro-Sang Corporation, BioPure Corporation, Sangart

May 16, 2022

Global Market Vision provides an in-depth analysis of Artificial Blood Market, which evaluates business solutions, evaluates R&D, application, benefits, advantage, scope, and operations. This report provides an in-depth analysis and development of the industry’s key manufacturers, key drivers, opportunities, challenges, and international suppliers, along with an in-depth study of risks and barriers to entry. It […] The post Artificial Blood Market Size Analysis, Evolving Opportunities Investigated for Forecast Period 2022-2029 | Dextro-Sang Corporation, BioPure Corporation, Sangart appeared first on Archyworldys.

Sangart Frequently Asked Questions (FAQ)

  • When was Sangart founded?

    Sangart was founded in 1998.

  • Where is Sangart's headquarters?

    Sangart's headquarters is located at 6175 Lusk Boulevard, San Diego.

  • What is Sangart's latest funding round?

    Sangart's latest funding round is Series G - II.

  • How much did Sangart raise?

    Sangart raised a total of $180.36M.

  • Who are the investors of Sangart?

    Investors of Sangart include Gambro, ODIN Forvaltning AS, Life Equity Sweden, Jefferies Financial Group, GZ Group and 4 more.

  • Who are Sangart's competitors?

    Competitors of Sangart include Oceanit, Cathay Industrial Biotech, Akron Biotechnology, Hemarina, Biodel and 12 more.

Compare Sangart to Competitors

Hemarina Logo

Hemarina is a privately held biotechnology company focused on the research and development of oxygen-carriers for medical and industrial applications. Hemarina's approach to the development of oxygen transport agents is based on the observation of marine invertebrate colonizing extreme environments and the study of their respiratory adaptations. Hemarina's lead product, Hemarina M-101, is designed to deliver oxygen effectively and efficiently to cells, tissues, organs at risk of oxygen deprivation. Hemarina has already passed a panel of strong proof of concepts obtained during in-vitro and pre-clinical trials.


Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.


WesaGen is a biopharmaceutical company founded by Dr.Mustapha Abdelouahed, Ph.D., with expertise in Immunology, Hemostasis, Coagulation, Cell & Molecular Biology of Vessels, and Dr. Jack Lawler, Ph.D., Professor at Harvard Medical School. WesaGen is engaged in the near-term development of technologies to diagnose type 2 heparin-induced thrombocytopenia (or HIT, a life-threatening condition); the development of a line of and potent anti-angiogenic therapeutic drugs to treat cancer; and research and development based on a new nanoscale drug delivery platform technology.

Jeio Tech Logo
Jeio Tech

Jeio Tech is a manufacturer and international supplier of laboratory equipment. Jeio Tech and the Lab Companion brand under which it markets itself offers shakers, baths, hoods, test chambers, baths and circulatory units for meausring cells, photometers, refract meters, electrophoresis chambers, chromatography columns, rotary evaporators and rheometers, general incubators for cultivating thermopile bacteria, germs and colon bacilli, microorganism, and organism cultivation for life science. Industries which use for the company's products include molecular biology, cell culture cultivation, fermentation for pharmacy/ biotech, hybridization studies, medical researches, genetic research and microbiology, general pharmacy, clinical science, chemistry and biology.

Cell Therapeutics

CTI is committed to developing, acquiring, and commercializing innovative treatments for cancer. In the company's pursuit of making cancer more treatable, they are developing a diversified portfolio of oncology products focused on identifying and developing new, less toxic, and more effective ways to treat cancer.

Bridge to Life Logo
Bridge to Life

Bridge to Life is a biotechnology company that is focused on developing organ preservation solution technologies. Its products include a cold storage solution, a machine perfusion solution, and a sodium chloride solution for slush preparation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.